Mayne Pharma
78 drugs in NADAC|65 Generic,13 Brand
View Recalls (7)Mayne Pharma lists 78 NDCs in the CMS NADAC file (65 generic, 13 brand), at an average NADAC of $33.66 per unit, with a week-over-week move of +1.6% across products that moved. The firm's full portfolio, pricing trend, and FDA recalls are listed below.
Total Drugs
78
65G / 13B
Avg Price / Unit
$33.6632
$0.09 – $2315.29
Avg 7d Change
+1.55%
Across 28 drugs with changes
7d Activity
of 78 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
Isotretinoin market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Retinoid therapeutic class
Review the broader class where Mayne Pharma has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Mayne Pharma make?
Mayne Pharma lists 78 NDCs in the CMS NADAC file — 65 generic and 13 brand products.
What is the average price of Mayne Pharma drugs?
The average NADAC across Mayne Pharma's portfolio is $33.6632 per unit, ranging from $0.0907 to $2315.2857.
What types of drugs does Mayne Pharma make?
Mayne Pharma makes drugs across 24 FDA pharmacologic classes. The most common by NDC count are Retinoid (14), Estrogen (7), Tetracycline-class Drug (4), Central Nervous System Stimulant (4), Nitroimidazole Antimicrobial (4).
Has Mayne Pharma had any drug recalls?
7 FDA recalls are matched to Mayne Pharma in the openFDA feed, most recently on Jun 9, 2022.
How has Mayne Pharma's pricing changed recently?
Over the past 7 days, 14 Mayne Pharma products rose and 14 fell, with a portfolio-wide average change of +1.6%.
FDA Recalls (7)
Recalls matched by company name. Verify current status with FDA.
Clonidine Transdermal System, USP 0.3 mg/day, 4 Patches (NDC 51862-455-01) per Carton (51862-455-04), Rx only, Manufactured for: Mayne Pharma Greenville, NC 27834
Defective Delivery System: Out of specification for release liner removal force results at the 3-month CRT stability timepoint.
Lexette (halobetasol propionate) Topical Foam, 0.05% 50 g canisters, Rx ONLY, Distributed by: Mayne Pharma Greenville, NC 27834, NDC 51862-604-50
CGMP Deviation: Difficulty dispensing/does not dispense or dispensing liquid instead of foam.
Carbidopa and Levodopa Tablets, USP 25 mg/250mg, 100 ct bottle, Rx Only, Mayne Pharma, Greenville, NC 27834. NDC 51862-858-01
Product Mix-Up: A foreign tablet was found in bottle.
Oxycodone and Acetaminophen Tablets, USP, 5 mg*/325 mg, 100-count bottle, Rx Only, Manufactured by: Mayne Pharma, Greenville, NC 27834, NDC 68308-841-01.
Labeling: Incorrect or Missing Lot and/or Exp Date: Lot FG10517 is mislabeled on the primary container with Lot FG01517, shipper labels and invoices contain the correct lot number of FG10517.
Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-295-10.
Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.
Liothyronine Sodium Tablets, USP 25 mcg ,100-count bottles, Rx Only, Distributed by Perrigo Minneapolis, MN 55427, NDC 0574-0222-01
Failed Dissolution Specifications.
Bromfenac Ophthalmic Solution 0.09%, a) 2.5 mL bottles (NDC 0378-7110-35) and b) 5 mL bottles (NDC 00378-7109-35), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505
Lack of Assurance of Sterility: Failed preservative effectiveness test